Alergia e Imunologia
Revisão sistemática: Combinação de dose fixa de beta-agonista e esteroide inalatório, usada quando necessário, é clinicamente eficaz em adultos e adolescentes com asma leve.
14 Mai, 2021 | 09:56hCovid-19: A maioria das pessoas admitidas em hospital depois da vacinação foram infectadas antes que a imunização pudesse se desenvolver, mostra pesquisa.
10 Mai, 2021 | 11:22h
Comentário no Twitter
"#Covid19: Most people admitted to hospital after vaccination were infected before immunity could develop, research" https://t.co/wi30LkafC7
"…highlighting the importance of maintaining social distancing & understanding that immunity develops over time…"#ScienceUpFirst!
— Timothy Caulfield (@CaulfieldTim) May 7, 2021
Estudo de coorte: Eventos arteriais, tromboembolismo venoso, trombocitopenia e sangramento após vacinação com Oxford-AstraZeneca ChAdOx1-S: 11 eventos tromboembólicos venosos em excesso por 100.000 vacinações; 2,5 tromboses venosas cerebrais em excesso por 100.000 vacinações.
7 Mai, 2021 | 10:48hEditorial: Thromboembolism and the Oxford-AstraZeneca vaccine – The BMJ
Comentários: Thrombosis and bleeding after the Oxford-AstraZeneca covid-19 vaccination – The BMJ Opinion E Putting risks into context: covid-19 vaccines and blood clots – The BMJ Opinion E Expert reaction to study from Denmark and Norway looking at rare blood clots after the Oxford-AstraZeneca vaccine – Science Media Centre
Comentário no Twitter
NEW research sheds more light on rate of rare blood clots after Oxford-AstraZeneca vaccine
Rate of adverse events low; benefits of the vaccine still outweigh risks in most situations, say researchershttps://t.co/LslgvzWlWi @Pottegard
— The BMJ (@bmj_latest) May 6, 2021
O enigma COVID-19: decifrando a fisiopatologia e os fenótipos de uma nova doença.
7 Mai, 2021 | 10:44h
Comentário no Twitter
We forget that covid-19 is a new disease, never having been seen until late 2019, w/ different features than any prior illness. A truly outstanding review today on its pathophysiology https://t.co/8gx2w8r1xf @LancetRespirMed @osuchm and colleagues pic.twitter.com/WGIfI2nb9B
— Eric Topol (@EricTopol) May 6, 2021
Estudo observacional no Catar: Vacina da Pfizer–BioNTech se mostrou 89,5% eficaz contra a variante B.1.1.7 e 75% eficaz contra a variante B.1.351. A eficácia da vacina contra doença grave, crítica ou fatal com qualquer variante do SARS-CoV-2 foi de 97,4%.
6 Mai, 2021 | 07:45h
Comentário no Twitter
📍GET BOTH DOSES! Great variants & #COVID19 vaccine news—Pfizer/BioNTech vaccine had great efficacy of 89.5% vs #B117 🇬🇧 variant & 75% vs #B1351 🇿🇦 variant for infection—but only with 2 doses. The 1 dose efficacy was just ~29% vs #B117 & ~17% vs #B1351. 🧵https://t.co/SprUfggnmh pic.twitter.com/VDWHiLsQLL
— Eric Feigl-Ding (@DrEricDing) May 6, 2021
Receptores de transplante de órgãos continuam vulneráveis à Covid-19 mesmo depois da segunda dose da vacina.
6 Mai, 2021 | 07:42hEstudo Original: Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients – JAMA
Estudo de coorte mostra resposta imunológica inadequada à vacina de mRNA do SARS-CoV-2 entre receptores de transplante renal.
6 Mai, 2021 | 07:40h
Comentário no Twitter
The studies of mRNA vax in people with transplants are getting bigger: still the same message. Some protection, but not enough. This time, 308 people with kidney transplants in Israel, BNT-Pfizer vaccine https://t.co/Otvt8F11my
— Hilda Bastian, PhD (@hildabast) May 6, 2021
[Preprint] Anticorpos do SARS-Cov-2 permanecem detectáveis 12 meses após a infecção, e sua magnitude está associada com a idade e a gravidade da COVID-19.
5 Mai, 2021 | 09:41hComentário: SARS-CoV-2 antibodies are detectable up to a year after infection, finds study – News Medical
Comentário no Twitter
Ahhh… A year has passed since people with Covid-19 were enrolled in a longitudinal study at 7 US military hospitals. Only a small number checked 12 months later, but signs of immunity still. Immune responses lasting even after milder infection https://t.co/VWsqG8gulT Preprint
— Hilda Bastian, PhD (@hildabast) May 2, 2021
Infecção prévia por SARS-Cov-2 gera resposta às variantes após a primeira dose de vacina
4 Mai, 2021 | 10:10hEstudo Original: Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose – Science
Comentário no Twitter (fio – clique para saber mais)
Just published @ScienceMagazine
"After one dose, individuals with *prior infection* showed enhanced T cell immunity, antibody secreting memory B cell response to spike and neutralizing antibodies effective against B.1.1.7 and B.1.351." 👍https://t.co/7cCVM6iqdP pic.twitter.com/GiC43bjwZZ— Eric Topol (@EricTopol) April 30, 2021
Estudo: Cefazolina é segura para a maioria dos pacientes que desenvolvem reação de hipersensibilidade não mediada por IgE à nafcilina
4 Mai, 2021 | 09:44h
Comentário no Twitter
New case series found 90% tolerated switching to cefazolin out of 80 patients who experienced non-IgE hypersensitivity reactions to nafcillin.https://t.co/YbFeWS4n4k
Our previous metas-analysis https://t.co/sJBjrx4a3r found higher odds of these reactions with nafcillin. pic.twitter.com/SIWcSuPcct— Antibiotic Tweets 🦠 (@khalideljaaly) April 28, 2021